MKC9989

小分子

MKC9989

M647927-5mg

5mg

≥98%

-20°C储存

超低温冰袋运输

MKC9989 is a Hydroxy aryl aldehydes ( HAA ) inhibitor and also inhibits IRE1α with an IC 50 of 0.23 to 44 μM. In Vitro At 10 μM concentration, MKC9989 completely inhibits both basal and thapsigargin induced splicing of XBP1 mRNA. These effects are observed even in cells pre-treated with thapsigargin, indicating that MKC9989 can fully reverse the onset of XPB1 splicing after the UPR is initiated. In parallel analysis, MKC9989, significantly stabilizes the RIDD target CD59 mRNA when co-administered with thapsigargin relative to thapsigargin treatment alone and modestly increases levels of CD59 mRNA in non-stressed cells, the latter likely reflects the inhibition of baseline RIDD activity. In contrast to effects on XBP1 splicing, MKC9989 moderately stabilizes CD59 levels when administered 2 hour post treatment with thapsigargin. Finally, the potency of MKC9989 against the splicing of XBP1 mRNA (EC 50 =0.33 μM) is comparable to its potency against RNA cleavage in vitro. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 0.23 to 44 μM (IRE1α)

MKC9989 是一种羟基芳基醛（HAA）抑制剂，也能抑制 IRE1α，其 IC 50 为 0.23 至 44 μM。

1338934-20-5

C17H20O7

336.34 g/mol

89542001

CC1=C(C(=O)OC2=C(C(=C(C=C12)OC)O)C=O)CCOCCOC

7-hydroxy-6-methoxy-3-[2-(2-methoxyethoxy)ethyl]-4-methyl-2-oxochromene-8-carbaldehyde

1S/C17H20O7/c1-10-11(4-5-23-7-6-21-2)17(20)24-16-12(10)8-14(22-3)15(19)13(16)9-18/h8-9,19H,4-7H2,1-3H3

QSVDQIXSUDHAOF-UHFFFAOYSA-N

CC1=C(C(=O)OC2=C(C(=C(C=C12)OC)O)C=O)CCOCCOC

89542001

MKC9989

DMSO : ≥ 50 mg/mL (148.66 mM)

1

7

8

336.121 Da

336.121 Da

91.300 Ų

24

0

487

0

1

1.4